These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 17707057

  • 1. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    Williams CR, Tabios R, Linehan WM, Neckers L.
    J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 3. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 4. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
    Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G.
    Cancer Res; 2003 Dec 01; 63(23):8393-9. PubMed ID: 14679001
    [Abstract] [Full Text] [Related]

  • 5. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells.
    Meyer PN, Roychowdhury S, Kini AR, Alkan S.
    Leuk Res; 2008 Jan 01; 32(1):143-9. PubMed ID: 17617451
    [Abstract] [Full Text] [Related]

  • 6. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].
    Yu WJ, Rao Q, Wang M, Tian Z, Xu ZF, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 01; 28(10):677-80. PubMed ID: 18399173
    [Abstract] [Full Text] [Related]

  • 7. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L.
    Clin Cancer Res; 2001 Jul 01; 7(7):2076-84. PubMed ID: 11448926
    [Abstract] [Full Text] [Related]

  • 8. [The heat shock protein 90 inhibitor induces apoptosis and differentiation of Kasumi-1 and its mechanisms].
    Yu WJ, Rao Q, Wang M, Tian Z, Liu XR, Lin D, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 01; 26(12):728-31. PubMed ID: 16620576
    [Abstract] [Full Text] [Related]

  • 9. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
    Myung SJ, Yoon JH, Kim BH, Lee JH, Jung EU, Lee HS.
    J Pharmacol Exp Ther; 2009 Jul 01; 330(1):276-82. PubMed ID: 19329756
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 01; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
    Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2005 Jan 01; 55(1):21-32. PubMed ID: 15338192
    [Abstract] [Full Text] [Related]

  • 12. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Fujii Y, Kato T, Kubota N, Fujimori A, Niwa O, Okayasu R.
    Oncol Rep; 2010 Jan 01; 23(1):199-203. PubMed ID: 19956882
    [Abstract] [Full Text] [Related]

  • 13. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1068-77. PubMed ID: 16882944
    [Abstract] [Full Text] [Related]

  • 14. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.
    Cancer Res; 2009 Jun 01; 69(11):4750-9. PubMed ID: 19458065
    [Abstract] [Full Text] [Related]

  • 15. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Australian Prostate Cancer BioResource, Tilley WD, Butler LM.
    Clin Cancer Res; 2012 Jul 01; 18(13):3562-70. PubMed ID: 22573351
    [Abstract] [Full Text] [Related]

  • 16. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.
    Tsui KH, Feng TH, Hsieh WC, Chang PL, Juang HH.
    Acta Pharmacol Sin; 2008 Nov 01; 29(11):1334-41. PubMed ID: 18954528
    [Abstract] [Full Text] [Related]

  • 17. Potent triazolothione inhibitor of heat-shock protein-90.
    Feldman RI, Mintzer B, Zhu D, Wu JM, Biroc SL, Yuan S, Emayan K, Chang Z, Chen D, Arnaiz DO, Bryant J, Ge XS, Whitlow M, Adler M, Polokoff MA, Li WW, Ferrer M, Sato T, Gu JM, Shen J, Tseng JL, Dinter H, Buckman B.
    Chem Biol Drug Des; 2009 Jul 01; 74(1):43-50. PubMed ID: 19519743
    [Abstract] [Full Text] [Related]

  • 18. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):935-40. PubMed ID: 18760546
    [Abstract] [Full Text] [Related]

  • 19. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D.
    Clin Cancer Res; 2008 Mar 15; 14(6):1831-9. PubMed ID: 18347186
    [Abstract] [Full Text] [Related]

  • 20. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
    Evans S, Dizeyi N, Abrahamsson PA, Persson J.
    Anticancer Res; 2009 Oct 15; 29(10):3917-24. PubMed ID: 19846929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.